中華民國血液病學會

1. Which statement is false?

A. According to 2018 ESMO clinical practice guidelines Hb ≦ 10g /dL, Platelets < 100x109 /L, or IgM levels > 40 g/L is the laboratory indications for initiation of therapy.

B. According to NCCN 2023 (version 1), the symptoms related to hyperviscosity, anemia, cytopenia, or organomegaly are the indications for treatment.

C. According to NCCN 2023 (version 1), retinal examination once a year if serum IgM level > 3,000 mg/dL is recommended.

D. According to NCCN 2023 (version 1), it is recommended to consider therapy in asymptomatic patients with serum IgM level > 6,000 mg/dL.

2. Which statement is false?

A. It was confirmed by studies that symptomatic hyperviscosity would impact overall survival in WM patients.

B. A serum IgM level > 6,000 mg/dL at diagnosis was associated with symptomatic hyperviscosity.

C. Pneumocystis jirovecii pneumonia [PJP] prophylaxis should be considered for patients receiving bendamustine/rituximab.

D. Everolimus is one of the useful therapy in previously treated WM/LPL

3. Which statement is false about treatment response criteria in NCCN?

A. VGPR: A ≥90% reduction of serum IgM and decrease in adenopathy/organomegaly (if present at baseline) on physical examination or on CT scan. No new symptoms or signs of active disease.

B. PR: A ≥50% reduction of serum IgM and decrease in adenopathy/organomegaly (if present at baseline) on physical examination or on CT scan.4 No new symptoms or signs of active disease.

C. MR: A ≥30% but <50% reduction of serum IgM. No new symptoms or signs of active disease.

D. CR: IgM in normal range, and disappearance of monoclonal protein by immunofixation; no histologic evidence of bone marrow involvement, and resolution of any adenopathy/organomegaly.

The correct answer is as follows

1.Which statement of is false?

A: (A) According to 2018 ESMO clinical practice guidelines Hb ≦ 10g /dL, Platelets < 100x109 /L, or IgM levels > 40 g/L is the laboratory indications for initiation of therapy.

2.Which statement of is false?

A: (A) It was confirmed by studies that symptomatic hyperviscosity would impact overall survival in WM patients.

3.Which statement is false about treatment response criteria in NCCN?

A: (C) MR: A ≥30% but <50% reduction of serum IgM. No new symptoms or signs of active disease.